Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities

Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities

Hepatocellular carcinoma (HCC) remains a major health problem worldwide with a continuous increasing prevalence. Despite the introduction of targeted therapies like the multi-kinase inhibitor sorafenib, treatment outcomes are not encouraging. The prognosis of advanced HCC is still dismal, underlying...

Full description

Bibliographic Details
Main Authors: Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Vasiliki E. Georgakopoulou, Panagiotis Sarantis, Efstathios A. Antoniou, Michalis V. Karamouzis, Afroditi Nonni, Dimitrios Schizas, Evangelos Diamantis, Evangelos Koustas, Paraskevi Farmaki, Athanasios Syllaios, Alexandros Patsouras, Konstantinos Kontzoglou, Nikolaos Trakas, Dimitrios Dimitroulis
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Journal of Personalized Medicine
Subjects:
histone
deacetylase
inhibitors
HDAC
HDACI
hepatocellular carcinoma
Online Access:https://www.mdpi.com/2075-4426/11/3/223

Internet

https://www.mdpi.com/2075-4426/11/3/223

Similar Items